Breast Cancer Clinical Trial 20213172

[LCID Study Number: 20213172 ]

A011801: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib

The purpose of this study is to evaluate how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.

Disease/Condition: Breast Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital; Addison Gilbert Hospital; Beverly Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 04457596 on ClinicalTrials.gov
Protocol #: 20213172 
Principal Investigator(s): Corrine Zarwan
Study Coordinator(s): Amanda Cossar
Trial Phase: Sponsor Initiated Study Phase 3